Systemic toxicities of trastuzumab-emtansine predict tumor response in HER2+ metastatic breast cancer.

Tang, Shou-Ching; Capra, Carter L; Ajebo, Germame H; Meza-Junco, Judith; Mairs, Simon; Craft, Barbara S; Zhu, Xiaofu; Maihle, Nita; Hillegass, William B

Tang, Shou-Ching; Capra, Carter L; Ajebo, Germame H; Meza-Junco, Judith; Mairs, Simon; Craft, Barbara S; Zhu, Xiaofu; Maihle, Nita; Hillegass, William B.

Afiliação

Tang SC; Cancer Center and Research Institute, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Capra CL; Alabama Oncology, Birmingham, Alabama, USA.
Ajebo GH; Department of Medicine, Division of Hematology/Oncology, Georgia Cancer Center, Augusta University, Augusta, Georgia, USA.
Meza-Junco J; Division of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada.
Mairs S; Division of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada.
Craft BS; Cancer Center and Research Institute, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Zhu X; Division of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada.
Maihle N; Cancer Center and Research Institute, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Hillegass WB; Departments of Medicine and Data Science, University of Mississippi Medical Center, Jackson, Mississippi, USA.

Int J Cancer ; 2021 Apr 12.

Article em En | MEDLINE | ID: mdl-33844843

Palavras-chave

antibody-drug conjugate; clinical outcomes; correlative study; systemic toxicities; trastuzumab-emtansine

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google